Log in

NYSE:DGX - Quest Diagnostics Stock Price, Forecast & News

$112.85
+0.69 (+0.62 %)
(As of 02/16/2020 03:04 PM ET)
Add
Today's Range
$111.71
Now: $112.85
$112.85
50-Day Range
$104.47
MA: $108.46
$112.85
52-Week Range
$82.59
Now: $112.85
$113.00
Volume670,765 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio17.97
Dividend YieldN/A
BetaN/A
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Services
SectorN/A
CUSIP74834L10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees46,000
Next Earnings Date4/28/2020 (Estimated)
OptionableOptionable

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.


Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Thursday, January 30th. Investors of record on Tuesday, April 7th will be given a dividend of $0.56 per share on Tuesday, April 21st. This represents a $2.24 dividend on an annualized basis and a yield of 1.98%. The ex-dividend date of this dividend is Monday, April 6th. This is an increase from Quest Diagnostics's previous quarterly dividend of $0.53. View Quest Diagnostics' Dividend History.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) issued its earnings results on Thursday, January, 30th. The medical research company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.07. The medical research company had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.92 billion. The business's revenue for the quarter was up 4.7% on a year-over-year basis. During the same period last year, the business earned $1.36 earnings per share. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share (EPS) guidance of at least $6.60 for the period, compared to the Thomson Reuters consensus estimate of $6.73. The company issued revenue guidance of $7.80 billion to $7.90 billion, compared to the consensus revenue estimate of $7.89 billion.

What price target have analysts set for DGX?

16 analysts have issued 12 month target prices for Quest Diagnostics' shares. Their forecasts range from $85.00 to $122.00. On average, they anticipate Quest Diagnostics' share price to reach $108.93 in the next year. This suggests that the stock has a possible downside of 3.5%. View Analyst Price Targets for Quest Diagnostics.

What is the consensus analysts' recommendation for Quest Diagnostics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 3 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Quest Diagnostics.

What are Wall Street analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:
  • 1. According to Zacks Investment Research, "In recent times, Quest Diagnostics has been refocusing on its diagnostic information services wing and disciplined capital deployment. Its acquisitions and collaborations with hospitals continue to act as key drivers. We are upbeat about Quest Diagnostics’ Preferred Network partnership with UnitedHealthcare. In the past three months, the company has outperformed its industry. The company exited second-quarter 2019 with better-than-expected earnings as well as revenues On the flip side, the company is currently facing several reimbursement issues. Also, a rise in patient concession along with certain reserve adjustments caused a decline in revenue per requisition. Also, adjusted earnings declined on a year-over-year basis. This apart, escalating costs and a tough competitive landscape are concerns." (9/30/2019)
  • 2. Evercore ISI analysts commented, "We spent time on the west coast last week (LA + SF weather right now >>> Diagnostics (CFO and IR). Post solid 1H results after a reset in sentiment, numbers, and multiples last year, it is safe to say investor perception has recovered somewhat and the focus has shifted back towards the longer term path with the possibility of regulatory easing (particularly as organic volumes surprised last Q)." (8/8/2019)
  • 3. Canaccord Genuity analysts commented, "We have written before that large labs (LH, DGX) and most of the rest of the non- specialized lab industry will face major challenges in 2019 and beyond. That said, we believe Quest is better positioned than LabCorp as Quest is a share gainer related to the UNH contract. DGX indicated that its UNH volumes build each week, and we expect DGX will drive 2-3 points of to offset the ~260bps headwind related to reimbursement. We think the 2019 bar is set appropriately and DGX likely can recover more in 2H/19. DGX is paying a 2.4% dividend yield. We maintain our BUY, trim our estimates and our PT to $97, which uses a 14.4x multiple on our ’20 Adj. EPS of $6.75. Q4/18 results. Adj. EPS of $1.36 (-3% Y/Y%) matched our/Street’s ~$1.36, while revs of $1,839M (-1.4% Y/Y) missed our/Street’s ~$1,878M (+0.7%). Rev./req." (2/18/2019)

Has Quest Diagnostics been receiving favorable news coverage?

Media stories about DGX stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Quest Diagnostics earned a news impact score of 0.2 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Quest Diagnostics.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,970,000 shares, an increase of 14.4% from the December 31st total of 3,470,000 shares. Based on an average daily volume of 818,400 shares, the days-to-cover ratio is presently 4.9 days. Currently, 3.0% of the shares of the company are sold short. View Quest Diagnostics' Current Options Chain.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Honeywell International (HON), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), United Rentals (URI), Accenture (ACN) and AutoZone (AZO).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.93%), Victory Capital Management Inc. (2.99%), Victory Capital Management Inc. (2.96%), Marshall Wace North America L.P. (1.69%), Boston Partners (1.48%) and Amundi Pioneer Asset Management Inc. (1.10%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Michael J Deppe, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics.

Which major investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Schroder Investment Management Group, Bank of New York Mellon Corp, FMR LLC, Bank of America Corp DE, Levin Easterly Partners LLC, PGGM Investments and Sei Investments Co.. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics.

Which major investors are buying Quest Diagnostics stock?

DGX stock was acquired by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Goldman Sachs Group Inc., Lord Abbett & CO. LLC, State Street Corp, Marshall Wace North America L.P., Victory Capital Management Inc., M&G Investment Management Ltd. and Becker Capital Management Inc.. View Insider Buying and Selling for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $112.85.


MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  449 (Vote Outperform)
Underperform Votes:  839 (Vote Underperform)
Total Votes:  1,288
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel